Publications - Page 25 sur 43 - RespiFIL - Filière de santé des maladies respiratoires rares

Voici les publications scientifiques relatives aux maladies respiratoires rares auxquelles les membres de la filière ont contribué, classées par groupes de pathologies (depuis juillet 2021).

Hypertension pulmonaire (HTP) 31/08/23
PDE5 to keep them alive: The use of phosphodiesterase type-5 inhibitors in severe pulmonary hypertension associated with interstitial lung disease.

Weatherald J, Humbert M.

Respirology. 2022 Nov 1.
Hypertension pulmonaire (HTP) 31/08/23
Impact of pulmonary hypertension on lung cancer management.

Durin L, Noël-Savina E, Héluain V, Mattei P, Mazières J, Prévot G.

Respir Med Res. 2022 Nov;82:100964.
Hypertension pulmonaire (HTP) 31/08/23
The evolving landscape of pulmonary arterial hypertension clinical trials.

Weatherald J, Boucly A, Peters A, Montani D, Prasad K, Psotka MA, Zannad F, Gomberg-Maitland M, McLaughlin V, Simonneau G, Humbert M; Evolving Landscape of Pulmonary Arterial Hypertension and Redesigning Pulmonary Arterial Hypertension Clinical Trials Task Force of the 18th Global CardioVascular Clinical Trialists Forum.

Lancet. 2022 Nov 26;400(10366):1884-1898.
Hypertension pulmonaire (HTP) 31/08/23
The thromboxane receptor antagonist NTP42 promotes beneficial adaptation and preserves cardiac function in experimental models of right heart overload

Mulvaney EP, Renzo F, Adão R, Dupre E, Bialesova L, Salvatore V, Reid HM, Conceição G, Grynblat J, Llucià-Valldeperas A, Michel JB, Brás-Silva C, Laurent CE, Howard LS, Montani D, Humbert M, Vonk Noordegraaf A, Perros F, Mendes-Ferreira P, Kinsella BT.

Front Cardiovasc Med. 2022 Dec 14;9:1063967.
Hypertension pulmonaire (HTP) 31/08/23
Lipidomic Profile Analysis of Lung Tissues Revealed Lipointoxication in Pulmonary Veno-Occlusive Disease.

Khoury S, Beauvais A, Colas J, Saint-Martin Willer A, Perros F, Humbert M, Vandebrouck C, Montani D, Ferreira T, Antigny F.

Biomolecules. 2022 Dec 14;12(12):1878.
Hypertension pulmonaire (HTP) 31/08/23
Molecular Function and Contribution of TBX4 in Development and Disease.

Karolak JA, Welch CL, Mosimann C, Bzdega K, West JD, Montani D, Eyries M, Mullen MP, Abman SH, Prapa M, Gräf S, Morrell NW, Hemnes AR, Perros F, Hamid R, Logan MPO, Whitsett J, Galambos C, Stankiewicz P, Chung WK, Austin ED; TBX4Life Initiative.

Am J Respir Crit Care Med. 2022 Nov 11.
Hypertension pulmonaire (HTP) 31/08/23
Frequency and predictors for chronic thromboembolic pulmonary hypertension after a first unprovoked pulmonary embolism: Results from PADIS studies.

Fauché A, Presles E, Sanchez O, Jaïs X, Le Mao R, Robin P, Pernod G, Bertoletti L, Jego P, Parent F, Lemarié CA, Leven F, Le Roux PY, Salaun PY, Nonent M, Girard P, Lacut K, Savale L, Mélac S, Guégan M, Mismetti P, Laporte S, Leroyer C, Montani D, Couturaud F, Tromeur C; PADIS-PE Investigators.

J Thromb Haemost. 2022 Dec;20(12):2850-2861.
Hypertension pulmonaire (HTP) 31/08/23
Quantifying leg muscle deoxygenation during incremental cycling in hypoxemic patients with fibrotic interstitial lung disease.

Marillier M, Bernard AC, Verges S, Moran-Mendoza O, Neder JA.

Clin Physiol Funct Imaging. 2022 Dec 29.
Hypertension pulmonaire (HTP) 31/08/23
Biomarkers of haemodynamic severity of systemic sclerosis-associated pulmonary arterial hypertension by serum proteome analysis.

Sanges S, Rice L, Tu L, Valenzi E, Cracowski JL, Montani D, Mantero JC, Ternynck C, Marot G, Bujor AM, Hachulla E, Launay D, Humbert M, Guignabert C, Lafyatis R.

Ann Rheum Dis. 2022 Dec 5:ard-2022-223237.
Hypertension pulmonaire (HTP) 31/08/23
Identifying new drugs associated with pulmonary arterial hypertension: A WHO pharmacovigilance database disproportionality analysis.

Hlavaty A, Roustit M, Montani D, Chaumais MC, Guignabert C, Humbert M, Cracowski JL, Khouri C.

Br J Clin Pharmacol. 2022 Dec;88(12):5227-5237.

FILTRER :

Par mot clé

Par maladies

Réinitialiser les filtres

PDE5 to keep them alive: The use of phosphodiesterase type-5 inhibitors in severe pulmonary hypertension associated with interstitial lung disease.

Impact of pulmonary hypertension on lung cancer management.

The evolving landscape of pulmonary arterial hypertension clinical trials.

The thromboxane receptor antagonist NTP42 promotes beneficial adaptation and preserves cardiac function in experimental models of right heart overload

Lipidomic Profile Analysis of Lung Tissues Revealed Lipointoxication in Pulmonary Veno-Occlusive Disease.

Molecular Function and Contribution of TBX4 in Development and Disease.

Frequency and predictors for chronic thromboembolic pulmonary hypertension after a first unprovoked pulmonary embolism: Results from PADIS studies.

Quantifying leg muscle deoxygenation during incremental cycling in hypoxemic patients with fibrotic interstitial lung disease.

Biomarkers of haemodynamic severity of systemic sclerosis-associated pulmonary arterial hypertension by serum proteome analysis.

Identifying new drugs associated with pulmonary arterial hypertension: A WHO pharmacovigilance database disproportionality analysis.